Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Exclusion Criteria

• •1. Have an active, clinically significant unstable medical condition within 1 month before screening
• •2. Have a known history of long QT syndrome or cardiac arrhythmia
• •3. Have a known history of neuroleptic malignant syndrome
• •4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
• •5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors
• •6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7 days, before the start of the study
• •7. Have a known history of substance dependence, substance (drug) or alcohol abuse within 3 months before the start of the study
• •8. Have a significant risk of suicidal or violent behavior
• •9. Have received an investigational drug within 30 days before the start of the study or plan to use an investigational drug (other than NBI-98854) during the study
• •10. Are currently participating in another NBI-98854 clinical study
• •11. Are pregnant (for females)